nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—ABCB1—Mitomycin—urinary bladder cancer	0.165	0.362	CbGbCtD
Amantadine—SLC22A2—Cisplatin—urinary bladder cancer	0.13	0.284	CbGbCtD
Amantadine—ABCB1—Gemcitabine—urinary bladder cancer	0.0474	0.104	CbGbCtD
Amantadine—ABCB1—Cisplatin—urinary bladder cancer	0.0345	0.0757	CbGbCtD
Amantadine—ABCB1—Etoposide—urinary bladder cancer	0.0339	0.0743	CbGbCtD
Amantadine—ABCB1—Doxorubicin—urinary bladder cancer	0.0231	0.0507	CbGbCtD
Amantadine—ABCB1—Methotrexate—urinary bladder cancer	0.0224	0.0491	CbGbCtD
Amantadine—GRIN2D—prostate gland—urinary bladder cancer	0.00706	0.14	CbGeAlD
Amantadine—DDC—renal system—urinary bladder cancer	0.00334	0.0664	CbGeAlD
Amantadine—SLC22A2—renal system—urinary bladder cancer	0.00275	0.0547	CbGeAlD
Amantadine—DDC—female reproductive system—urinary bladder cancer	0.00268	0.0532	CbGeAlD
Amantadine—SIGMAR1—prostate gland—urinary bladder cancer	0.00264	0.0524	CbGeAlD
Amantadine—GRIN2A—vagina—urinary bladder cancer	0.00259	0.0515	CbGeAlD
Amantadine—MAOB—prostate gland—urinary bladder cancer	0.00252	0.0501	CbGeAlD
Amantadine—SIGMAR1—seminal vesicle—urinary bladder cancer	0.00223	0.0443	CbGeAlD
Amantadine—MAOB—seminal vesicle—urinary bladder cancer	0.00213	0.0424	CbGeAlD
Amantadine—SLC22A1—renal system—urinary bladder cancer	0.00194	0.0386	CbGeAlD
Amantadine—SIGMAR1—smooth muscle tissue—urinary bladder cancer	0.00187	0.0371	CbGeAlD
Amantadine—SIGMAR1—urethra—urinary bladder cancer	0.00176	0.0351	CbGeAlD
Amantadine—MAOB—renal system—urinary bladder cancer	0.00172	0.0342	CbGeAlD
Amantadine—MAOB—urethra—urinary bladder cancer	0.00169	0.0336	CbGeAlD
Amantadine—DDC—lymph node—urinary bladder cancer	0.00157	0.0311	CbGeAlD
Amantadine—SLC22A1—vagina—urinary bladder cancer	0.00141	0.028	CbGeAlD
Amantadine—MAOB—female reproductive system—urinary bladder cancer	0.00138	0.0274	CbGeAlD
Amantadine—SIGMAR1—vagina—urinary bladder cancer	0.0013	0.0258	CbGeAlD
Amantadine—MAOB—vagina—urinary bladder cancer	0.00125	0.0247	CbGeAlD
Amantadine—ABCB1—prostate gland—urinary bladder cancer	0.00092	0.0183	CbGeAlD
Amantadine—SIGMAR1—lymph node—urinary bladder cancer	0.000842	0.0167	CbGeAlD
Amantadine—MAOB—lymph node—urinary bladder cancer	0.000806	0.016	CbGeAlD
Amantadine—ABCB1—seminal vesicle—urinary bladder cancer	0.000778	0.0155	CbGeAlD
Amantadine—ABCB1—epithelium—urinary bladder cancer	0.000676	0.0134	CbGeAlD
Amantadine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000644	0.00163	CcSEcCtD
Amantadine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000639	0.00162	CcSEcCtD
Amantadine—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.000638	0.00162	CcSEcCtD
Amantadine—Insomnia—Fluorouracil—urinary bladder cancer	0.000638	0.00162	CcSEcCtD
Amantadine—Somnolence—Gemcitabine—urinary bladder cancer	0.000637	0.00162	CcSEcCtD
Amantadine—Anorexia—Cisplatin—urinary bladder cancer	0.000637	0.00162	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000634	0.00161	CcSEcCtD
Amantadine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000633	0.00161	CcSEcCtD
Amantadine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000629	0.00159	CcSEcCtD
Amantadine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000628	0.00159	CcSEcCtD
Amantadine—ABCB1—renal system—urinary bladder cancer	0.000627	0.0125	CbGeAlD
Amantadine—Somnolence—Fluorouracil—urinary bladder cancer	0.000627	0.00159	CcSEcCtD
Amantadine—Hypotension—Cisplatin—urinary bladder cancer	0.000625	0.00158	CcSEcCtD
Amantadine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000623	0.00158	CcSEcCtD
Amantadine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000621	0.00157	CcSEcCtD
Amantadine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000619	0.00157	CcSEcCtD
Amantadine—Fatigue—Gemcitabine—urinary bladder cancer	0.000618	0.00157	CcSEcCtD
Amantadine—Confusional state—Etoposide—urinary bladder cancer	0.000617	0.00157	CcSEcCtD
Amantadine—ABCB1—urethra—urinary bladder cancer	0.000616	0.0122	CbGeAlD
Amantadine—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000614	0.00156	CcSEcCtD
Amantadine—Constipation—Gemcitabine—urinary bladder cancer	0.000613	0.00156	CcSEcCtD
Amantadine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000613	0.00156	CcSEcCtD
Amantadine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000612	0.00155	CcSEcCtD
Amantadine—Asthenia—Thiotepa—urinary bladder cancer	0.000612	0.00155	CcSEcCtD
Amantadine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000609	0.00154	CcSEcCtD
Amantadine—Ataxia—Doxorubicin—urinary bladder cancer	0.000608	0.00154	CcSEcCtD
Amantadine—Dysphagia—Epirubicin—urinary bladder cancer	0.000604	0.00153	CcSEcCtD
Amantadine—Neutropenia—Methotrexate—urinary bladder cancer	0.000603	0.00153	CcSEcCtD
Amantadine—Pruritus—Thiotepa—urinary bladder cancer	0.000603	0.00153	CcSEcCtD
Amantadine—Paraesthesia—Cisplatin—urinary bladder cancer	0.0006	0.00152	CcSEcCtD
Amantadine—Tachycardia—Etoposide—urinary bladder cancer	0.000598	0.00152	CcSEcCtD
Amantadine—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000597	0.00151	CcSEcCtD
Amantadine—Dyspnoea—Cisplatin—urinary bladder cancer	0.000596	0.00151	CcSEcCtD
Amantadine—Skin disorder—Etoposide—urinary bladder cancer	0.000595	0.00151	CcSEcCtD
Amantadine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000592	0.0015	CcSEcCtD
Amantadine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000591	0.0015	CcSEcCtD
Amantadine—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.00059	0.0015	CcSEcCtD
Amantadine—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000589	0.00149	CcSEcCtD
Amantadine—Anorexia—Etoposide—urinary bladder cancer	0.000584	0.00148	CcSEcCtD
Amantadine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000583	0.00148	CcSEcCtD
Amantadine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000581	0.00147	CcSEcCtD
Amantadine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000581	0.00147	CcSEcCtD
Amantadine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000577	0.00146	CcSEcCtD
Amantadine—Hypotension—Etoposide—urinary bladder cancer	0.000572	0.00145	CcSEcCtD
Amantadine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000567	0.00144	CcSEcCtD
Amantadine—Neutropenia—Epirubicin—urinary bladder cancer	0.000564	0.00143	CcSEcCtD
Amantadine—Dizziness—Thiotepa—urinary bladder cancer	0.000564	0.00143	CcSEcCtD
Amantadine—Dysphagia—Doxorubicin—urinary bladder cancer	0.000558	0.00142	CcSEcCtD
Amantadine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000557	0.00141	CcSEcCtD
Amantadine—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000551	0.0014	CcSEcCtD
Amantadine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000551	0.0014	CcSEcCtD
Amantadine—Paraesthesia—Etoposide—urinary bladder cancer	0.00055	0.0014	CcSEcCtD
Amantadine—Dyspnoea—Etoposide—urinary bladder cancer	0.000546	0.00139	CcSEcCtD
Amantadine—Somnolence—Etoposide—urinary bladder cancer	0.000544	0.00138	CcSEcCtD
Amantadine—Vomiting—Thiotepa—urinary bladder cancer	0.000542	0.00138	CcSEcCtD
Amantadine—Rash—Thiotepa—urinary bladder cancer	0.000537	0.00136	CcSEcCtD
Amantadine—Dermatitis—Thiotepa—urinary bladder cancer	0.000537	0.00136	CcSEcCtD
Amantadine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000537	0.00136	CcSEcCtD
Amantadine—Headache—Thiotepa—urinary bladder cancer	0.000534	0.00135	CcSEcCtD
Amantadine—Decreased appetite—Etoposide—urinary bladder cancer	0.000532	0.00135	CcSEcCtD
Amantadine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000529	0.00134	CcSEcCtD
Amantadine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000528	0.00134	CcSEcCtD
Amantadine—Fatigue—Etoposide—urinary bladder cancer	0.000528	0.00134	CcSEcCtD
Amantadine—Constipation—Etoposide—urinary bladder cancer	0.000524	0.00133	CcSEcCtD
Amantadine—Neutropenia—Doxorubicin—urinary bladder cancer	0.000522	0.00132	CcSEcCtD
Amantadine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000519	0.00132	CcSEcCtD
Amantadine—Asthenia—Gemcitabine—urinary bladder cancer	0.000514	0.00131	CcSEcCtD
Amantadine—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.00051	0.00129	CcSEcCtD
Amantadine—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.00051	0.00129	CcSEcCtD
Amantadine—Pruritus—Gemcitabine—urinary bladder cancer	0.000507	0.00129	CcSEcCtD
Amantadine—Nausea—Thiotepa—urinary bladder cancer	0.000506	0.00128	CcSEcCtD
Amantadine—Urethral disorder—Methotrexate—urinary bladder cancer	0.000506	0.00128	CcSEcCtD
Amantadine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000505	0.00128	CcSEcCtD
Amantadine—ABCB1—female reproductive system—urinary bladder cancer	0.000502	0.00998	CbGeAlD
Amantadine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000502	0.00127	CcSEcCtD
Amantadine—Pruritus—Fluorouracil—urinary bladder cancer	0.000499	0.00127	CcSEcCtD
Amantadine—Visual impairment—Methotrexate—urinary bladder cancer	0.000497	0.00126	CcSEcCtD
Amantadine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000492	0.00125	CcSEcCtD
Amantadine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000491	0.00124	CcSEcCtD
Amantadine—Body temperature increased—Etoposide—urinary bladder cancer	0.000484	0.00123	CcSEcCtD
Amantadine—Eye disorder—Methotrexate—urinary bladder cancer	0.000482	0.00122	CcSEcCtD
Amantadine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000482	0.00122	CcSEcCtD
Amantadine—Asthenia—Cisplatin—urinary bladder cancer	0.00048	0.00122	CcSEcCtD
Amantadine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000479	0.00122	CcSEcCtD
Amantadine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000477	0.00121	CcSEcCtD
Amantadine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000476	0.00121	CcSEcCtD
Amantadine—Urethral disorder—Epirubicin—urinary bladder cancer	0.000474	0.0012	CcSEcCtD
Amantadine—Angiopathy—Methotrexate—urinary bladder cancer	0.000468	0.00119	CcSEcCtD
Amantadine—Dizziness—Fluorouracil—urinary bladder cancer	0.000466	0.00118	CcSEcCtD
Amantadine—Visual impairment—Epirubicin—urinary bladder cancer	0.000466	0.00118	CcSEcCtD
Amantadine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000465	0.00118	CcSEcCtD
Amantadine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000465	0.00118	CcSEcCtD
Amantadine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000457	0.00116	CcSEcCtD
Amantadine—Alopecia—Methotrexate—urinary bladder cancer	0.000456	0.00116	CcSEcCtD
Amantadine—Vomiting—Gemcitabine—urinary bladder cancer	0.000456	0.00116	CcSEcCtD
Amantadine—ABCB1—vagina—urinary bladder cancer	0.000454	0.00903	CbGeAlD
Amantadine—Mental disorder—Methotrexate—urinary bladder cancer	0.000452	0.00115	CcSEcCtD
Amantadine—Rash—Gemcitabine—urinary bladder cancer	0.000452	0.00115	CcSEcCtD
Amantadine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000452	0.00115	CcSEcCtD
Amantadine—Eye disorder—Epirubicin—urinary bladder cancer	0.000451	0.00115	CcSEcCtD
Amantadine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000451	0.00114	CcSEcCtD
Amantadine—Malnutrition—Methotrexate—urinary bladder cancer	0.000449	0.00114	CcSEcCtD
Amantadine—Headache—Gemcitabine—urinary bladder cancer	0.000449	0.00114	CcSEcCtD
Amantadine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000448	0.00114	CcSEcCtD
Amantadine—Vomiting—Fluorouracil—urinary bladder cancer	0.000448	0.00114	CcSEcCtD
Amantadine—Rash—Fluorouracil—urinary bladder cancer	0.000445	0.00113	CcSEcCtD
Amantadine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000444	0.00113	CcSEcCtD
Amantadine—Headache—Fluorouracil—urinary bladder cancer	0.000442	0.00112	CcSEcCtD
Amantadine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000441	0.00112	CcSEcCtD
Amantadine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00044	0.00112	CcSEcCtD
Amantadine—Asthenia—Etoposide—urinary bladder cancer	0.000439	0.00111	CcSEcCtD
Amantadine—Angiopathy—Epirubicin—urinary bladder cancer	0.000438	0.00111	CcSEcCtD
Amantadine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000438	0.00111	CcSEcCtD
Amantadine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000435	0.0011	CcSEcCtD
Amantadine—Pruritus—Etoposide—urinary bladder cancer	0.000433	0.0011	CcSEcCtD
Amantadine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000432	0.00109	CcSEcCtD
Amantadine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000431	0.00109	CcSEcCtD
Amantadine—Alopecia—Epirubicin—urinary bladder cancer	0.000427	0.00108	CcSEcCtD
Amantadine—Nausea—Gemcitabine—urinary bladder cancer	0.000426	0.00108	CcSEcCtD
Amantadine—Vomiting—Cisplatin—urinary bladder cancer	0.000425	0.00108	CcSEcCtD
Amantadine—Vision blurred—Methotrexate—urinary bladder cancer	0.000423	0.00107	CcSEcCtD
Amantadine—Mental disorder—Epirubicin—urinary bladder cancer	0.000423	0.00107	CcSEcCtD
Amantadine—Rash—Cisplatin—urinary bladder cancer	0.000421	0.00107	CcSEcCtD
Amantadine—Dermatitis—Cisplatin—urinary bladder cancer	0.000421	0.00107	CcSEcCtD
Amantadine—Malnutrition—Epirubicin—urinary bladder cancer	0.000421	0.00107	CcSEcCtD
Amantadine—Diarrhoea—Etoposide—urinary bladder cancer	0.000419	0.00106	CcSEcCtD
Amantadine—Nausea—Fluorouracil—urinary bladder cancer	0.000419	0.00106	CcSEcCtD
Amantadine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000418	0.00106	CcSEcCtD
Amantadine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000415	0.00105	CcSEcCtD
Amantadine—Tension—Epirubicin—urinary bladder cancer	0.000413	0.00105	CcSEcCtD
Amantadine—Nervousness—Epirubicin—urinary bladder cancer	0.000408	0.00104	CcSEcCtD
Amantadine—Angiopathy—Doxorubicin—urinary bladder cancer	0.000406	0.00103	CcSEcCtD
Amantadine—Dizziness—Etoposide—urinary bladder cancer	0.000405	0.00103	CcSEcCtD
Amantadine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000403	0.00102	CcSEcCtD
Amantadine—Leukopenia—Methotrexate—urinary bladder cancer	0.000402	0.00102	CcSEcCtD
Amantadine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000399	0.00101	CcSEcCtD
Amantadine—Nausea—Cisplatin—urinary bladder cancer	0.000397	0.00101	CcSEcCtD
Amantadine—Vision blurred—Epirubicin—urinary bladder cancer	0.000396	0.00101	CcSEcCtD
Amantadine—Alopecia—Doxorubicin—urinary bladder cancer	0.000395	0.001	CcSEcCtD
Amantadine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000392	0.000994	CcSEcCtD
Amantadine—Convulsion—Methotrexate—urinary bladder cancer	0.000389	0.000988	CcSEcCtD
Amantadine—Vomiting—Etoposide—urinary bladder cancer	0.000389	0.000988	CcSEcCtD
Amantadine—Malnutrition—Doxorubicin—urinary bladder cancer	0.000389	0.000987	CcSEcCtD
Amantadine—Agitation—Epirubicin—urinary bladder cancer	0.000386	0.000981	CcSEcCtD
Amantadine—Rash—Etoposide—urinary bladder cancer	0.000386	0.00098	CcSEcCtD
Amantadine—Dermatitis—Etoposide—urinary bladder cancer	0.000386	0.000979	CcSEcCtD
Amantadine—Headache—Etoposide—urinary bladder cancer	0.000384	0.000973	CcSEcCtD
Amantadine—Tension—Doxorubicin—urinary bladder cancer	0.000382	0.000969	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00038	0.000964	CcSEcCtD
Amantadine—Nervousness—Doxorubicin—urinary bladder cancer	0.000378	0.000959	CcSEcCtD
Amantadine—Leukopenia—Epirubicin—urinary bladder cancer	0.000376	0.000955	CcSEcCtD
Amantadine—Palpitations—Epirubicin—urinary bladder cancer	0.000372	0.000943	CcSEcCtD
Amantadine—Confusional state—Methotrexate—urinary bladder cancer	0.00037	0.000938	CcSEcCtD
Amantadine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000367	0.000931	CcSEcCtD
Amantadine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000367	0.00093	CcSEcCtD
Amantadine—Convulsion—Epirubicin—urinary bladder cancer	0.000364	0.000925	CcSEcCtD
Amantadine—Nausea—Etoposide—urinary bladder cancer	0.000364	0.000923	CcSEcCtD
Amantadine—Hypertension—Epirubicin—urinary bladder cancer	0.000363	0.000921	CcSEcCtD
Amantadine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00036	0.000913	CcSEcCtD
Amantadine—Agitation—Doxorubicin—urinary bladder cancer	0.000358	0.000907	CcSEcCtD
Amantadine—Anxiety—Epirubicin—urinary bladder cancer	0.000357	0.000905	CcSEcCtD
Amantadine—Skin disorder—Methotrexate—urinary bladder cancer	0.000356	0.000904	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000356	0.000902	CcSEcCtD
Amantadine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000355	0.0009	CcSEcCtD
Amantadine—Dry mouth—Epirubicin—urinary bladder cancer	0.00035	0.000888	CcSEcCtD
Amantadine—Anorexia—Methotrexate—urinary bladder cancer	0.00035	0.000887	CcSEcCtD
Amantadine—Leukopenia—Doxorubicin—urinary bladder cancer	0.000348	0.000884	CcSEcCtD
Amantadine—Confusional state—Epirubicin—urinary bladder cancer	0.000346	0.000878	CcSEcCtD
Amantadine—Palpitations—Doxorubicin—urinary bladder cancer	0.000344	0.000872	CcSEcCtD
Amantadine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000343	0.000871	CcSEcCtD
Amantadine—Oedema—Epirubicin—urinary bladder cancer	0.000343	0.000871	CcSEcCtD
Amantadine—Hypotension—Methotrexate—urinary bladder cancer	0.000343	0.00087	CcSEcCtD
Amantadine—Convulsion—Doxorubicin—urinary bladder cancer	0.000337	0.000855	CcSEcCtD
Amantadine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000337	0.000854	CcSEcCtD
Amantadine—Hypertension—Doxorubicin—urinary bladder cancer	0.000336	0.000852	CcSEcCtD
Amantadine—Tachycardia—Epirubicin—urinary bladder cancer	0.000335	0.00085	CcSEcCtD
Amantadine—Skin disorder—Epirubicin—urinary bladder cancer	0.000333	0.000846	CcSEcCtD
Amantadine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000332	0.000842	CcSEcCtD
Amantadine—Insomnia—Methotrexate—urinary bladder cancer	0.000332	0.000842	CcSEcCtD
Amantadine—Anxiety—Doxorubicin—urinary bladder cancer	0.00033	0.000838	CcSEcCtD
Amantadine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000329	0.000836	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000329	0.000835	CcSEcCtD
Amantadine—Anorexia—Epirubicin—urinary bladder cancer	0.000327	0.00083	CcSEcCtD
Amantadine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000327	0.00083	CcSEcCtD
Amantadine—Somnolence—Methotrexate—urinary bladder cancer	0.000326	0.000827	CcSEcCtD
Amantadine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000324	0.000822	CcSEcCtD
Amantadine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000323	0.000819	CcSEcCtD
Amantadine—Hypotension—Epirubicin—urinary bladder cancer	0.000321	0.000814	CcSEcCtD
Amantadine—Confusional state—Doxorubicin—urinary bladder cancer	0.00032	0.000812	CcSEcCtD
Amantadine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000319	0.000809	CcSEcCtD
Amantadine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000318	0.000806	CcSEcCtD
Amantadine—Oedema—Doxorubicin—urinary bladder cancer	0.000318	0.000806	CcSEcCtD
Amantadine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000317	0.000803	CcSEcCtD
Amantadine—Fatigue—Methotrexate—urinary bladder cancer	0.000316	0.000802	CcSEcCtD
Amantadine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000311	0.00079	CcSEcCtD
Amantadine—Insomnia—Epirubicin—urinary bladder cancer	0.00031	0.000788	CcSEcCtD
Amantadine—Tachycardia—Doxorubicin—urinary bladder cancer	0.00031	0.000786	CcSEcCtD
Amantadine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000308	0.000783	CcSEcCtD
Amantadine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000308	0.000782	CcSEcCtD
Amantadine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000307	0.000779	CcSEcCtD
Amantadine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000306	0.000776	CcSEcCtD
Amantadine—Somnolence—Epirubicin—urinary bladder cancer	0.000305	0.000774	CcSEcCtD
Amantadine—Anorexia—Doxorubicin—urinary bladder cancer	0.000303	0.000768	CcSEcCtD
Amantadine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000302	0.000767	CcSEcCtD
Amantadine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000302	0.000767	CcSEcCtD
Amantadine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000298	0.000757	CcSEcCtD
Amantadine—Hypotension—Doxorubicin—urinary bladder cancer	0.000297	0.000753	CcSEcCtD
Amantadine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000296	0.000752	CcSEcCtD
Amantadine—Fatigue—Epirubicin—urinary bladder cancer	0.000296	0.000751	CcSEcCtD
Amantadine—ABCB1—lymph node—urinary bladder cancer	0.000294	0.00584	CbGeAlD
Amantadine—Constipation—Epirubicin—urinary bladder cancer	0.000293	0.000745	CcSEcCtD
Amantadine—Body temperature increased—Methotrexate—urinary bladder cancer	0.00029	0.000736	CcSEcCtD
Amantadine—Insomnia—Doxorubicin—urinary bladder cancer	0.000287	0.000729	CcSEcCtD
Amantadine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000285	0.000724	CcSEcCtD
Amantadine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000283	0.000718	CcSEcCtD
Amantadine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000283	0.000718	CcSEcCtD
Amantadine—Somnolence—Doxorubicin—urinary bladder cancer	0.000282	0.000716	CcSEcCtD
Amantadine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00028	0.000709	CcSEcCtD
Amantadine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000276	0.0007	CcSEcCtD
Amantadine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000274	0.000696	CcSEcCtD
Amantadine—Fatigue—Doxorubicin—urinary bladder cancer	0.000274	0.000695	CcSEcCtD
Amantadine—Constipation—Doxorubicin—urinary bladder cancer	0.000272	0.000689	CcSEcCtD
Amantadine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000271	0.000688	CcSEcCtD
Amantadine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00027	0.000686	CcSEcCtD
Amantadine—Asthenia—Methotrexate—urinary bladder cancer	0.000263	0.000668	CcSEcCtD
Amantadine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000262	0.000664	CcSEcCtD
Amantadine—Pruritus—Methotrexate—urinary bladder cancer	0.000259	0.000658	CcSEcCtD
Amantadine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000253	0.000642	CcSEcCtD
Amantadine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000251	0.000637	CcSEcCtD
Amantadine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000251	0.000637	CcSEcCtD
Amantadine—Asthenia—Epirubicin—urinary bladder cancer	0.000246	0.000625	CcSEcCtD
Amantadine—Pruritus—Epirubicin—urinary bladder cancer	0.000243	0.000616	CcSEcCtD
Amantadine—Dizziness—Methotrexate—urinary bladder cancer	0.000243	0.000615	CcSEcCtD
Amantadine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000235	0.000596	CcSEcCtD
Amantadine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000234	0.000594	CcSEcCtD
Amantadine—Vomiting—Methotrexate—urinary bladder cancer	0.000233	0.000592	CcSEcCtD
Amantadine—Rash—Methotrexate—urinary bladder cancer	0.000231	0.000587	CcSEcCtD
Amantadine—Dermatitis—Methotrexate—urinary bladder cancer	0.000231	0.000586	CcSEcCtD
Amantadine—Headache—Methotrexate—urinary bladder cancer	0.00023	0.000583	CcSEcCtD
Amantadine—Asthenia—Doxorubicin—urinary bladder cancer	0.000228	0.000578	CcSEcCtD
Amantadine—Dizziness—Epirubicin—urinary bladder cancer	0.000227	0.000576	CcSEcCtD
Amantadine—Pruritus—Doxorubicin—urinary bladder cancer	0.000225	0.00057	CcSEcCtD
Amantadine—Vomiting—Epirubicin—urinary bladder cancer	0.000218	0.000554	CcSEcCtD
Amantadine—Nausea—Methotrexate—urinary bladder cancer	0.000218	0.000553	CcSEcCtD
Amantadine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000217	0.000551	CcSEcCtD
Amantadine—Rash—Epirubicin—urinary bladder cancer	0.000216	0.000549	CcSEcCtD
Amantadine—Dermatitis—Epirubicin—urinary bladder cancer	0.000216	0.000549	CcSEcCtD
Amantadine—Headache—Epirubicin—urinary bladder cancer	0.000215	0.000546	CcSEcCtD
Amantadine—Dizziness—Doxorubicin—urinary bladder cancer	0.00021	0.000533	CcSEcCtD
Amantadine—Nausea—Epirubicin—urinary bladder cancer	0.000204	0.000517	CcSEcCtD
Amantadine—Vomiting—Doxorubicin—urinary bladder cancer	0.000202	0.000512	CcSEcCtD
Amantadine—Rash—Doxorubicin—urinary bladder cancer	0.0002	0.000508	CcSEcCtD
Amantadine—Dermatitis—Doxorubicin—urinary bladder cancer	0.0002	0.000508	CcSEcCtD
Amantadine—Headache—Doxorubicin—urinary bladder cancer	0.000199	0.000505	CcSEcCtD
Amantadine—Nausea—Doxorubicin—urinary bladder cancer	0.000189	0.000479	CcSEcCtD
Amantadine—SLC22A1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000136	0.00136	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000136	0.00136	CbGpPWpGaD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	0.000134	0.00134	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—RHOA—urinary bladder cancer	0.000133	0.00133	CbGpPWpGaD
Amantadine—MAOB—Metabolism—TYMP—urinary bladder cancer	0.000133	0.00133	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—HRAS—urinary bladder cancer	0.000131	0.00131	CbGpPWpGaD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	0.000131	0.00131	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—RHOA—urinary bladder cancer	0.00013	0.0013	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—FAS—urinary bladder cancer	0.000129	0.00129	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—HRAS—urinary bladder cancer	0.000128	0.00128	CbGpPWpGaD
Amantadine—DDC—Metabolism—RRM2—urinary bladder cancer	0.000123	0.00123	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—ERBB2—urinary bladder cancer	0.000123	0.00123	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTZ1—urinary bladder cancer	0.000123	0.00123	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—TP53—urinary bladder cancer	0.000122	0.00122	CbGpPWpGaD
Amantadine—MAOB—Metabolism—NAT2—urinary bladder cancer	0.00012	0.0012	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—CDK4—urinary bladder cancer	0.00012	0.0012	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—ERBB2—urinary bladder cancer	0.00012	0.0012	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.00012	0.0012	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—CDK4—urinary bladder cancer	0.000117	0.00117	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTO2—urinary bladder cancer	0.000116	0.00116	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NAT1—urinary bladder cancer	0.000116	0.00116	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—HRAS—urinary bladder cancer	0.000116	0.00116	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	0.000115	0.00115	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTZ1—urinary bladder cancer	0.000114	0.00114	CbGpPWpGaD
Amantadine—DDC—Metabolism—ENO2—urinary bladder cancer	0.000114	0.00114	CbGpPWpGaD
Amantadine—DDC—Metabolism—HPGDS—urinary bladder cancer	0.000114	0.00114	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000113	0.00113	CbGpPWpGaD
Amantadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	0.000112	0.00112	CbGpPWpGaD
Amantadine—DDC—Metabolism—GSTT1—urinary bladder cancer	0.000111	0.00111	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—PPARG—urinary bladder cancer	0.000109	0.00109	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTO2—urinary bladder cancer	0.000108	0.00108	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NAT1—urinary bladder cancer	0.000108	0.00108	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—HRAS—urinary bladder cancer	0.000108	0.00108	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—UGT2B7—urinary bladder cancer	0.000106	0.00106	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—PPARG—urinary bladder cancer	0.000106	0.00106	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—MMP9—urinary bladder cancer	0.000106	0.00106	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—CREBBP—urinary bladder cancer	0.000105	0.00105	CbGpPWpGaD
Amantadine—MAOB—Metabolism—RRM2—urinary bladder cancer	0.000104	0.00104	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—MMP9—urinary bladder cancer	0.000103	0.00103	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000103	0.00103	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	0.000102	0.00102	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—CREBBP—urinary bladder cancer	0.000102	0.00102	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	0.000101	0.00101	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	0.000101	0.00101	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—UGT2B7—urinary bladder cancer	9.92e-05	0.000992	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	9.89e-05	0.000989	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	9.82e-05	0.000982	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	9.81e-05	0.000981	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	9.79e-05	0.00098	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—SRC—urinary bladder cancer	9.73e-05	0.000973	CbGpPWpGaD
Amantadine—MAOB—Metabolism—HPGDS—urinary bladder cancer	9.6e-05	0.000961	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ENO2—urinary bladder cancer	9.6e-05	0.000961	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP4B1—urinary bladder cancer	9.58e-05	0.000958	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	9.53e-05	0.000953	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—SRC—urinary bladder cancer	9.48e-05	0.000949	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—RHOA—urinary bladder cancer	9.48e-05	0.000949	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	9.36e-05	0.000936	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GSTT1—urinary bladder cancer	9.31e-05	0.000932	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—RHOA—urinary bladder cancer	9.24e-05	0.000925	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	9.22e-05	0.000922	CbGpPWpGaD
Amantadine—DDC—Metabolism—NQO1—urinary bladder cancer	9.2e-05	0.00092	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—SLC19A1—urinary bladder cancer	9.05e-05	0.000905	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP4B1—urinary bladder cancer	8.93e-05	0.000893	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—HRAS—urinary bladder cancer	8.85e-05	0.000885	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PRSS3—urinary bladder cancer	8.82e-05	0.000882	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—ERBB2—urinary bladder cancer	8.78e-05	0.000878	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—ERBB2—urinary bladder cancer	8.56e-05	0.000856	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—EGFR—urinary bladder cancer	8.53e-05	0.000853	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SLC19A1—urinary bladder cancer	8.43e-05	0.000843	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—EGFR—urinary bladder cancer	8.31e-05	0.000831	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	8.29e-05	0.000829	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PRSS3—urinary bladder cancer	8.22e-05	0.000822	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—KRAS—urinary bladder cancer	8.05e-05	0.000806	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	8e-05	0.0008	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—KRAS—urinary bladder cancer	7.85e-05	0.000785	CbGpPWpGaD
Amantadine—MAOB—Metabolism—NQO1—urinary bladder cancer	7.74e-05	0.000774	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—HRAS—urinary bladder cancer	7.72e-05	0.000772	CbGpPWpGaD
Amantadine—DDC—Metabolism—GSTP1—urinary bladder cancer	7.67e-05	0.000767	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MMP9—urinary bladder cancer	7.53e-05	0.000753	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—HRAS—urinary bladder cancer	7.52e-05	0.000752	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MMP9—urinary bladder cancer	7.34e-05	0.000734	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	7.33e-05	0.000733	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	7.29e-05	0.00073	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	7.26e-05	0.000727	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—EP300—urinary bladder cancer	7.14e-05	0.000714	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	7.13e-05	0.000713	CbGpPWpGaD
Amantadine—DDC—Metabolism—TYMS—urinary bladder cancer	7.13e-05	0.000713	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—PTEN—urinary bladder cancer	7.05e-05	0.000705	CbGpPWpGaD
Amantadine—DDC—Metabolism—NCOR1—urinary bladder cancer	7.05e-05	0.000705	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—TYMP—urinary bladder cancer	7.05e-05	0.000705	CbGpPWpGaD
Amantadine—DDC—Metabolism—GSTM1—urinary bladder cancer	7.05e-05	0.000705	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—EP300—urinary bladder cancer	6.96e-05	0.000696	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—SRC—urinary bladder cancer	6.94e-05	0.000694	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—CXCL8—urinary bladder cancer	6.92e-05	0.000692	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—HRAS—urinary bladder cancer	6.85e-05	0.000685	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—SRC—urinary bladder cancer	6.77e-05	0.000677	CbGpPWpGaD
Amantadine—DDC—Metabolism—GPX1—urinary bladder cancer	6.75e-05	0.000675	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—EP300—urinary bladder cancer	6.72e-05	0.000673	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	6.7e-05	0.000671	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—HRAS—urinary bladder cancer	6.67e-05	0.000668	CbGpPWpGaD
Amantadine—DDC—Metabolism—ERCC2—urinary bladder cancer	6.63e-05	0.000663	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—TYMP—urinary bladder cancer	6.57e-05	0.000657	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GSTP1—urinary bladder cancer	6.46e-05	0.000646	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NAT2—urinary bladder cancer	6.37e-05	0.000638	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	6.37e-05	0.000637	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTO2—urinary bladder cancer	6.35e-05	0.000636	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NAT1—urinary bladder cancer	6.35e-05	0.000636	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	6.29e-05	0.000629	CbGpPWpGaD
Amantadine—DDC—Metabolism—MTHFR—urinary bladder cancer	6.23e-05	0.000623	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HDAC4—urinary bladder cancer	6.21e-05	0.000621	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—EGFR—urinary bladder cancer	6.08e-05	0.000609	CbGpPWpGaD
Amantadine—MAOB—Metabolism—TYMS—urinary bladder cancer	6e-05	0.0006	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NAT2—urinary bladder cancer	5.94e-05	0.000594	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GSTM1—urinary bladder cancer	5.93e-05	0.000593	CbGpPWpGaD
Amantadine—MAOB—Metabolism—NCOR1—urinary bladder cancer	5.93e-05	0.000593	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—EGFR—urinary bladder cancer	5.93e-05	0.000593	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	5.81e-05	0.000581	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—TNF—urinary bladder cancer	5.79e-05	0.00058	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—KRAS—urinary bladder cancer	5.75e-05	0.000575	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GPX1—urinary bladder cancer	5.68e-05	0.000568	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—TNF—urinary bladder cancer	5.65e-05	0.000565	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—KRAS—urinary bladder cancer	5.6e-05	0.00056	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ERCC2—urinary bladder cancer	5.58e-05	0.000558	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	5.5e-05	0.00055	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—RRM2—urinary bladder cancer	5.5e-05	0.00055	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.4e-05	0.00054	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	5.33e-05	0.000533	CbGpPWpGaD
Amantadine—MAOB—Metabolism—MTHFR—urinary bladder cancer	5.24e-05	0.000524	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	5.24e-05	0.000524	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	5.23e-05	0.000524	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	5.21e-05	0.000522	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GLI1—urinary bladder cancer	5.2e-05	0.00052	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—RRM2—urinary bladder cancer	5.13e-05	0.000513	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—HPGDS—urinary bladder cancer	5.1e-05	0.00051	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ENO2—urinary bladder cancer	5.1e-05	0.00051	CbGpPWpGaD
Amantadine—DDC—Metabolism—PPARG—urinary bladder cancer	5.05e-05	0.000505	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTT1—urinary bladder cancer	4.94e-05	0.000494	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	4.94e-05	0.000494	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—HRAS—urinary bladder cancer	4.89e-05	0.000489	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	4.88e-05	0.000488	CbGpPWpGaD
Amantadine—DDC—Metabolism—CREBBP—urinary bladder cancer	4.85e-05	0.000485	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PRSS3—urinary bladder cancer	4.82e-05	0.000482	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TP53—urinary bladder cancer	4.81e-05	0.000481	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—HRAS—urinary bladder cancer	4.76e-05	0.000476	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—HPGDS—urinary bladder cancer	4.75e-05	0.000475	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ENO2—urinary bladder cancer	4.75e-05	0.000475	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.71e-05	0.000471	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.63e-05	0.000463	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTT1—urinary bladder cancer	4.61e-05	0.000461	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.56e-05	0.000456	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.55e-05	0.000455	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.34e-05	0.000434	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.31e-05	0.000431	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PPARG—urinary bladder cancer	4.25e-05	0.000425	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4.22e-05	0.000422	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CXCL8—urinary bladder cancer	4.19e-05	0.000419	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NQO1—urinary bladder cancer	4.11e-05	0.000411	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CREBBP—urinary bladder cancer	4.08e-05	0.000409	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—HRAS—urinary bladder cancer	4.01e-05	0.000401	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTGS2—urinary bladder cancer	3.97e-05	0.000397	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TYMP—urinary bladder cancer	3.85e-05	0.000385	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NQO1—urinary bladder cancer	3.83e-05	0.000383	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.78e-05	0.000378	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—HRAS—urinary bladder cancer	3.74e-05	0.000374	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.7e-05	0.00037	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RBX1—urinary bladder cancer	3.56e-05	0.000357	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.52e-05	0.000352	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.49e-05	0.000349	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NAT2—urinary bladder cancer	3.48e-05	0.000348	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTEN—urinary bladder cancer	3.47e-05	0.000347	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTP1—urinary bladder cancer	3.43e-05	0.000343	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TSC1—urinary bladder cancer	3.35e-05	0.000335	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTGS2—urinary bladder cancer	3.34e-05	0.000335	CbGpPWpGaD
Amantadine—DDC—Metabolism—EP300—urinary bladder cancer	3.3e-05	0.000331	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTP1—urinary bladder cancer	3.19e-05	0.000319	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—JAG1—urinary bladder cancer	3.19e-05	0.000319	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—TYMS—urinary bladder cancer	3.18e-05	0.000319	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTM1—urinary bladder cancer	3.15e-05	0.000315	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NCOR1—urinary bladder cancer	3.15e-05	0.000315	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.1e-05	0.00031	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GPX1—urinary bladder cancer	3.01e-05	0.000302	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—RRM2—urinary bladder cancer	3.01e-05	0.000301	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—TYMS—urinary bladder cancer	2.97e-05	0.000297	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ERCC2—urinary bladder cancer	2.96e-05	0.000296	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NCOR1—urinary bladder cancer	2.93e-05	0.000294	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTM1—urinary bladder cancer	2.93e-05	0.000294	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTEN—urinary bladder cancer	2.92e-05	0.000292	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GPX1—urinary bladder cancer	2.81e-05	0.000281	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ENO2—urinary bladder cancer	2.78e-05	0.000278	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2.78e-05	0.000278	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—MTHFR—urinary bladder cancer	2.78e-05	0.000278	CbGpPWpGaD
Amantadine—MAOB—Metabolism—EP300—urinary bladder cancer	2.78e-05	0.000278	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ERCC2—urinary bladder cancer	2.76e-05	0.000276	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTT1—urinary bladder cancer	2.7e-05	0.00027	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—RHOA—urinary bladder cancer	2.7e-05	0.00027	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—MTHFR—urinary bladder cancer	2.59e-05	0.000259	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—S100B—urinary bladder cancer	2.58e-05	0.000258	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.53e-05	0.000253	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—RHOA—urinary bladder cancer	2.45e-05	0.000245	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.37e-05	0.000237	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NCOR1—urinary bladder cancer	2.32e-05	0.000232	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—IL2—urinary bladder cancer	2.26e-05	0.000226	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PPARG—urinary bladder cancer	2.26e-05	0.000226	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.24e-05	0.000224	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CREBBP—urinary bladder cancer	2.17e-05	0.000217	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCL8—urinary bladder cancer	2.15e-05	0.000215	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PPARG—urinary bladder cancer	2.1e-05	0.00021	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL2—urinary bladder cancer	2.05e-05	0.000206	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TERT—urinary bladder cancer	2.05e-05	0.000205	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CREBBP—urinary bladder cancer	2.02e-05	0.000202	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGFR3—urinary bladder cancer	1.88e-05	0.000188	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.87e-05	0.000187	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ESR1—urinary bladder cancer	1.82e-05	0.000183	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	1.77e-05	0.000178	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.74e-05	0.000174	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.72e-05	0.000172	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.72e-05	0.000172	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTGS2—urinary bladder cancer	1.65e-05	0.000165	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.65e-05	0.000165	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.62e-05	0.000162	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	1.6e-05	0.00016	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	1.58e-05	0.000158	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	1.57e-05	0.000157	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTEN—urinary bladder cancer	1.55e-05	0.000155	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.52e-05	0.000152	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	1.48e-05	0.000149	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—EP300—urinary bladder cancer	1.48e-05	0.000148	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	1.45e-05	0.000145	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTEN—urinary bladder cancer	1.44e-05	0.000144	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—EP300—urinary bladder cancer	1.38e-05	0.000138	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	1.34e-05	0.000134	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	1.27e-05	0.000127	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	1.26e-05	0.000126	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.23e-05	0.000123	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL2—urinary bladder cancer	1.21e-05	0.000121	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.18e-05	0.000118	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	1.18e-05	0.000118	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	1.15e-05	0.000115	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.14e-05	0.000115	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	1.14e-05	0.000114	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EP300—urinary bladder cancer	1.09e-05	0.000109	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SRC—urinary bladder cancer	1.06e-05	0.000106	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	9.7e-06	9.7e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MYC—urinary bladder cancer	9.49e-06	9.49e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	9.28e-06	9.29e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	8.77e-06	8.77e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTEN—urinary bladder cancer	8.46e-06	8.46e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—EP300—urinary bladder cancer	8.06e-06	8.07e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TP53—urinary bladder cancer	7.79e-06	7.8e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	7.45e-06	7.46e-05	CbGpPWpGaD
